Abstract
Objective To investigate the expression of matrix metalloproteinase (MMP)-2 and MMP-9 in the kidney of streptozocin (STZ)-induced diabetic rats and the effects of cyclosporine A (CsA) on their expression. Methods STZ-induced diabetic rats were randomly assigned to the non-treatment group (n=8), insulin intervention group (n=9), 1 μg·g-1·d-1 CsA before modeling group(n=9), 4 μg·g-1·d-1 CsA before modeling group(n=8), 8 μg·g-1·d-1 CsA before modeling group(n=8), 1 μg·g-1·d-1 CsA post modeling group (n=8), 4 μg·g-1·d-1 CsA post modeling group (n=7), or 8 μg·g-1·d-1 CsA post modeling group (n=7). Another 10 normal rats were used as controls. The renal expression of MMP-2 and MMP-9 mRNA and protein were determined by immunohistochemistry, reverse transcription-polymerase chain reaction (RT-PCR) and Western blot. The data were analyzed by one-factor analysis of variance and rectilinear correlation analysis. Results At 8 weeks, the 24-h urine microalbuminuria in the diabetic group was significantly higher than that in the normal control group ((5.80±3.23) and (1.24±0.21) mg/24 h, respectively; F=4.229, P 0.05). Conclusion The abnormal expression of MMP-2 and MMP-9 in the diabetic kidney could be downregulated by CsA. Diabetic nephropahty might be effectively prevented by immunosuppressive agents. Key words: Diabetes mellitus; Diabetic nephropathy; Matrix metalloproteinase; Immunosuppression; Cyclosporine A
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
